New hope for hepatitis c: triple therapy shows promise in late-stage trial

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main goal was to see if the virus became undetectable 24 weeks after treatment ended, indicating a sustained response.